News | December 14, 2024
Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio
The trademark rights for these brands will be transferred to Lupin by March next year.
The trademark rights for these brands will be transferred to Lupin by March next year.
Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus
The company had earlier announced about the approval received from the MHRA for Liraglutide
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Subscribe To Our Newsletter & Stay Updated
